Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 8.2% - Should You Sell?

Key Points

• Perspective Therapeutics shares fell 8.2% to $2.36, below both their 50-day moving average of $2.96 and 200-day moving average of $3.43.
• Analysts remain broadly bullish, with a consensus “Buy” rating and an average price target of $11.50, despite Bank of America lowering its target to $5.00 and maintaining a neutral rating.
• The clinical-stage radiopharmaceutical company beat quarterly EPS estimates, reporting a loss of $0.22 per share versus the expected $0.25 loss, but generated only $80,000 in revenue and continues to post substantial negative margins.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report)'s share price traded down 8.2% on Tuesday. The company traded as low as $2.30 and last traded at $2.36. Approximately 2,676,668 shares traded hands during mid-day trading, an increase of 6% from the average session volume of 2,520,738 shares. The stock had previously closed at $2.57.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CATX shares. Bank of America dropped their target price on Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, August 14th. BMO Capital Markets set a $11.00 price target on Perspective Therapeutics and gave the stock an "outperform" rating in a report on Tuesday, August 18th. Wedbush restated an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, September 15th. BTIG Research restated a "buy" rating on shares of Perspective Therapeutics in a report on Friday, July 24th. Finally, William Blair initiated coverage on shares of Perspective Therapeutics in a research note on Friday, September 18th. They set an "outperform" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $11.50.

Perspective Therapeutics Stock Down 8.2%

The business has a fifty day moving average price of $2.96 and a two-hundred day moving average price of $3.43.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.09 million. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. Sell-side analysts anticipate that Perspective Therapeutics, Inc. will post -0.98 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CATX. Wealth Effects LLC lifted its holdings in Perspective Therapeutics by 32.0% in the first quarter. Wealth Effects LLC now owns 33,000 shares of the company's stock valued at $138,000 after acquiring an additional 8,000 shares during the period. Abel Hall LLC purchased a new stake in Perspective Therapeutics in the 1st quarter worth approximately $49,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth approximately $84,000. Taylor & Morgan Wealth Management LLC grew its position in Perspective Therapeutics by 127.6% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company's stock valued at $225,000 after buying an additional 37,000 shares during the period. Finally, Quantinno Capital Management LP acquired a new stake in shares of Perspective Therapeutics during the 1st quarter valued at about $273,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc is a clinical-stage radiopharmaceutical biotechnology company developing precision-targeted alpha therapies for cancer. The company's approach combines tumor-targeting molecules with radioactive isotopes to deliver highly focused radiation to cancer cells while limiting exposure to surrounding healthy tissue.

Perspective's proprietary VMT platform is designed to support both diagnostic imaging and therapeutic applications. Its lead programs include VMT-α-NET, an investigational therapy targeting somatostatin receptor 2 for patients with neuroendocrine tumors, and VMT01, an investigational program targeting melanocortin 1 receptor-expressing cancers, including certain metastatic melanomas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.